COVID-19 Acute Respiratory Distress Syndrome

Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
1 program
1
XW001Phase 21 trial
Active Trials
NCT05083117WithdrawnEst. Apr 2022
Alliance Pharmaceuticals
1 program
1
ProTrans®Phase 11 trial
Active Trials
NCT04896853Active Not Recruiting9Est. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sciwind BiosciencesXW001
Alliance PharmaceuticalsProTrans®

Clinical Trials (2)

Total enrollment: 9 patients across 2 trials

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

Start: Oct 2021Est. completion: Apr 2022
Phase 2Withdrawn

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Start: May 2021Est. completion: May 20279 patients
Phase 1Active Not Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space